(Source: University of Birmingham)
A new test to detect COVID-19 antibodies in people with recent exposure, who are asymptomatic, or have mild symptoms has been launched by The Binding Site in collaboration with the University of Birmingham's Clinical Immunology Service
The unique SARS-CoV-2 Antibody ELISA has been developed to identify individuals who have had a mild, non-hospitalised disease course following SARS-CoV-2 exposure. This latest development has brought together the Binding Site's extensive experience in developing highly precise, accurate blood tests with the expertise of leading immunology and immunity experts at the University of Birmingham
The new test specifically detects antibodies (IgG, IgA and IgM) to the SARS-CoV-2 trimeric spike protein, which is an important protein for the virus infectivity.
Read more on University of Birmingham
